SNP marker associated with breast cancer chemotherapy toxicity and application of SNP marker

A technique for chemotherapy toxicity, breast cancer, applied in the field of SNP markers

Active Publication Date: 2017-10-17
复旦大学附属华山医院北院
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the application of SNP in the auxiliary diagnosis of breast cancer chemotherapy drug toxicity. If the breast cancer susceptibility SNP can be screened as a biomarker, its role in the auxiliary diagnosis of breast cancer chemotherapy drug t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • SNP marker associated with breast cancer chemotherapy toxicity and application of SNP marker
  • SNP marker associated with breast cancer chemotherapy toxicity and application of SNP marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] This embodiment is the collection of samples and the arrangement of sample data.

[0048] From September 2015 to November 2016, the inventor collected a large number of blood samples from breast cancer chemotherapy patients in Huashan Hospital (North Hospital) affiliated to Fudan University. After sorting out the sample data, the inventor selected 211 cases that met the following criteria: Standard samples, the sample selection criteria are as follows: (1) New-onset breast cancer patients who were admitted to the hospital for the first time and confirmed by histopathology or cytology, and their diagnosis was confirmed by at least two pathologists according to the standards issued by the World Health Organization; ( 2) The blood routine and liver and kidney function tests were normal before the first chemotherapy; (3) Received 4 cycles of cyclophosphamide + docetaxel + epirubicin chemotherapy; radiotherapy before or during chemotherapy was excluded (4) Have detailed bloo...

Embodiment 2

[0050] This embodiment is the peripheral blood DNA extraction, genotype detection and result analysis.

[0051] The specific steps are:

[0052] 1) Process the blood material, take 200 μl of blood sample.

[0053] 2) Add 20 μl Proteinase K solution and mix well.

[0054] 3) Add 200 μl of buffer solution GB, fully invert and mix, and place at 56°C for 10 minutes, during which invert and mix several times, the solution should become clear.

[0055] 4) Add 200 μl of absolute ethanol and mix thoroughly by inversion, at this time flocculent precipitation may appear.

[0056] 5) Add the solution and flocculent precipitate obtained in the previous step into an adsorption column CB3 (the adsorption column CB3 is placed in a collection tube), centrifuge at 12000rpm (~13400×g) for 30sec, pour off the waste liquid in the collection tube, and put the adsorption Column CB3 was placed in a collection tube.

[0057] 6) Add 500μl buffer GD to the adsorption column CB3 (check whether absol...

Embodiment 3

[0068] This embodiment is the production of a kit for detecting or predicting chemotherapy toxicity of breast cancer.

[0069] The production and operation process of the SNP kit is based on the detection technology of the Sequenom Mass ARRAY genotyping platform. The kit contains a batch of SNP-specific amplification primers (including the following primers: the rs2420946 amplification primer whose sequence is SEQ ID No:1 and SEQ ID No:2 and / or whose sequence is SEQ ID No:3 and SEQ ID No:4 rs2981578, see Table 1 for details), and common reagents required for corresponding PCR techniques, such as: dNTPs, MgCl 2 , double distilled water, etc., these commonly used reagents are well known to those skilled in the art, and there may also be standards and controls (such as standards for genotype determination and blank controls, etc.). The value of this kit is that it only needs peripheral blood and no other tissue samples, detects SNP through the most streamlined and specific ampli...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to two single-nucleotide polymorphism (SNP) sites rs2420946 and rs2981578 associated with a breast cancer on a fibroblast growth factor receptor (FGFR) gene for predicting breast cancer chemotherapy toxicity. Through development and application of an SNP biomarker and a breast cancer chemotherapy toxicity diagnosis kit, the toxicity reaction degree after breast cancer chemotherapy is predicted, thereby guiding medication for tumor chemotherapy and providing a new way for a clinical doctor for predicting prognosis of a patient.

Description

technical field [0001] The invention relates to the technical fields of genetic engineering and oncology, in particular, the invention relates to a SNP marker related to chemotherapy toxicity of breast cancer and its application. Background technique [0002] Breast cancer is a common malignant tumor that seriously endangers women's physical and mental health. The morbidity and mortality are increasing year by year. Globally, 1.2 million women suffer from breast cancer and 500,000 women die of breast cancer every year. Chemotherapy has become the main means of tumor treatment just like surgery and radiotherapy. With the continuous update of chemotherapy drugs, breast cancer chemotherapy has made remarkable progress. After years of clinical practice, paclitaxel and anthracycline have become the two cornerstones of breast cancer chemotherapy. They are widely used in the first-line and second-line treatment of locally advanced, recurrent and metastatic breast cancer. Standardi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/68C12N15/11
CPCC12Q1/6886C12Q2600/106C12Q2600/156
Inventor 李群益陈璐戚慧洁叶婷钟明康施孝金
Owner 复旦大学附属华山医院北院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap